A Network based Approach to Identify the Genetic Influence Caused by Associated Factors and Disorders for the Parkinsons Disease Progression

Abstract

Actual causes of Parkinsons disease (PD) are still unknown. In any case, a better comprehension of genetic and ecological influences to the PD and their interaction will assist physicians and patients to evaluate individual hazard for the PD, and definitely, there will be a possibility to find a way to reduce the progression of the PD. We introduced quantitative frameworks to reveal the complex relationship of various biasing genetic factors for the PD. In this study, we analyzed gene expression microarray data from the PD, ageing (AG), severe alcohol consumption (AC), type II diabetes (T2D), high body fat (HBF), hypercholesterolemia (HC), high dietary fat (HDF), red meat dietary (RMD), sedentary lifestyle (SL), smoking (SM), and control datasets. We have developed genetic associations of various factors with the PD based on the neighborhood-based benchmarking and multilayer network topology.\n\nWe identified 1343 significantly dysregulated genes in the PD patients compared to the healthy control, where we have 779 genes down regulated and 544 genes up regulated. 69 genes were highly expressed in both for the PD and alcohol consumption whereas the number of shared genes for the PD and the type II diabetes is 51. However, the PD shared 45, 43 and 42 significantly expressed genes with the ageing, high dietary fat and high body fat respectively. The PD shared less than 40 significant transcripts with other factors. Ontological and pathway analyses have identified significant gene ontology and molecular pathways that enhance our understanding of the fundamental molecular procedure of the PD progression. Therapeutic targets of the PD could be developed using these identified target genes, ontologies and pathways. Our formulated methodologies demonstrate a network-based approach to understand the disease mechanism and the causative reason of the PD, and the identification for therapeutic targets of the PD.